NCT04845646View on ClinicalTrials.gov

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 16, 2021

Primary Completion Date

June 10, 2021

Study Completion Date

June 10, 2021

Conditions
HealthyNAFLD
Interventions
DRUG

ASC41

5mg/tablet

DRUG

Itraconazole

200mg/capsule

DRUG

Phenytoin

300mg/capsule

Trial Locations (1)

78209

ICON early Phase Services LLC, San Antonio

Sponsors
All Listed Sponsors
lead

Gannex Pharma Co., Ltd.

INDUSTRY

NCT04845646 - DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD. | Biotech Hunter | Biotech Hunter